Novel multiomics platform for comprehensive disease insight and diagnosis.
The company aims to improve cancer outcomes through the power of dynamic biopsy.
Cambridge Science Park-company working with Mayr group at Imperial College.
It enables screening of millions of cells per hour and have expanded multiplexing capabilities.
Series A boost for synthetic genomics company founded in 2022.
Funds raised by the Cambridge company will boost PHA Europe’s five main areas for action.
Adaptive immunity company heads for next phase.
Novel degrader programmes in oncology and inflammatory diseases head for preclinical development.
Results to 30 June, 2024 reveal a strengthened balance sheet.
First Phase 2 clinical trial as FDA approval sought.
Next Cambridge meet-up is 18 September.
Find out who triumphed in the annual awards, held on the Wellcome Genome Campus.
University of Cambridge, Wellcome Sanger Institute and EMBL-EBI to team up.
It now has a 44 per cent stake in the clinical-stage biotechnology company.
